-
Taxonomy & unit
-
us-gaap: shares
-
Description
-
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
-
Summary
-
Allogene Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q2 2020 to Q4 2024.
- Allogene Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending December 31, 2024 was 195M shares, a 24.1% increase year-over-year.
- Allogene Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 195M shares, a 24.1% increase from 2023.
- Allogene Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 157M shares, a 9.63% increase from 2022.
- Allogene Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 143M shares, a 5.39% increase from 2021.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)